C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 223/16 (2006.01) A61K 31/55 (2006.01) A61P 25/16 (2006.01) C07D 405/04 (2006.01) C07D 409/04 (2006.01)
Patent
CA 2363695
The invention provides 2,3,4,5-tetrahydro-1H-3-benzazepines of general formula (I) wherein: R1 is hydrogen, halogen, C1-C4 alkyl, or CF3; R2 is hydrogen, methyl, or lower alkenyl of 3-5 carbon atoms; R3 and R4 together form a furan, dihydrofuran, thiophene, dihydrothiophene, cyclopentane or cyclohexane ring and R5 is hydrogen or R4 and R5 together form a furan, dihydrofuran, thiophene, dihydrothiophene, cyclopentane or cyclohexane ring and R3 is hydrogen; R6 is hydrogen, halogen, CF3, CN, NO2 or NH2; R7 is hydrogen, halogen, CF3, CN, NO2 or NH2. The specific combination of substituents: R1 = H, R2 = H and R4 and R5 together forming a cyclohexane ring is excluded, namely 1-(5,6,7,8-tetrahydronaphthalen-2-yl)-2,3,4,5-tetrahydro-1H- benzol[d]azepine-7,8-diol. The compounds of the invention provide therapeutic agents that selectively interact positively with postsynaptic dopamine D1 receptors in the striatum, directly or in-directly (termed dopamine D1 agonists) and are particularly valuable as anti-Parkinsonian agents.
La présente invention concerne des 2,3,4,5-tétrahydro-1H-3-benzazépines de formule (I) dans laquelle R?1¿ est un groupe hydrogène, halogène, C¿1?-C¿4? alkyle, ou CF¿3?, R?2¿ est un groupe hydrogène, méthyle, ou un alcényle inférieur à 3-5 atomes de carbone, R?3¿ et R?4¿ forment ensemble un noyau furane, dihydrofurane, thiophène, dihydrothiophène, cyclopentane ou cyclohexane et R?5¿ est un groupe hydrogène ou R?4¿ et R?5¿ forment ensemble un noyau furane, dihydrofurane, thiophène, dihydrothiophène, cyclopentane ou cyclohexane et R?3¿ est un groupe hydrogène, R?6¿ est un groupe hydrogène, halogène, CF¿3?, CN, NO¿2? ou NH¿2?, R?7¿ est un groupe hydrogène, halogène, CF¿3?, CN, NO¿2? ou NH¿2?. La combinaison spécifique de substituants R¿1? = H, R¿2? = H et R¿4? et R¿5? formant ensemble un noyau cyclohexane est exclue, notamment le 1-(5,6,7,8-tétrahydronaphthalène-2-yl)-2,3,4,5-tétrahydro-1H-benzol[d]azépine-7,8-diol. Les composés de l'invention permettent d'obtenir des agents thérapeutiques qui interagissent sélectivement avec les récepteurs D1 postsynaptiques de dopamine dans le striatum, directement ou indirectement (appelés agonistes D1 de dopamine) et sont particulièrement utiles comme anti-Parkinsoniens.
Cenes Limited
Shire Pharmaceutical Development Limited
Sim & Mcburney
LandOfFree
Dopamine d1 receptor agonist compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dopamine d1 receptor agonist compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine d1 receptor agonist compounds will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1342907